In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Health Ministry Dismisses Likelihood Of Compulsory Licensing For Antivirals Tamiflu and Relenza

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The South Korean government is not in a "desperate position" that would justify seeking compulsory licensing to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) in a protracted battle against A/H1N1, the health ministry said

You may also be interested in...



Korea Extends Closely Watched Pilot Project For Rare Disease Drug Refunds Three More Years

To maintain a stable supply of some multinational products for patients with rare diseases, the health ministry has extended its pilot refund system for three more years until 2015.

Korea FDA Issues Approval To Chong Kun Dang For Future Sales Of Generic Tamiflu

SEOUL - The Korea Food & Drug Administration granted approval to local South Korean Chong Kun Dang Pharmaceutical to sell its generic version of Roche's Tamiflu (oseltamivir) at some point in the future

Korea FDA Issues Approval To Chong Kun Dang For Future Sales Of Generic Tamiflu

SEOUL - The Korea Food & Drug Administration granted approval to local South Korean Chong Kun Dang Pharmaceutical to sell its generic version of Roche's Tamiflu (oseltamivir) at some point in the future

Related Content

UsernamePublicRestriction

Register

SC070136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel